Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022

BACKGROUND: On 2/27/2021, FDA authorized Janssen COVID-19 Vaccine (Ad.26.COV2.S) for use in individuals 18 years of age and older. Vaccine safety was monitored using the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance system, and v-safe, a smartphone-based surveillanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Emily Jane, Gee, Julianne, Marquez, Paige, Baggs, James, Abara, Winston E., McNeil, Michael M., Dimova, Rositsa B., Su, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264169/
https://www.ncbi.nlm.nih.gov/pubmed/37321898
http://dx.doi.org/10.1016/j.vaccine.2023.06.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264169/
https://www.ncbi.nlm.nih.gov/pubmed/37321898
http://dx.doi.org/10.1016/j.vaccine.2023.06.023

Ejemplares similares